Skip to main content
. 2014 Dec 10;6(4):2562–2572. doi: 10.18632/oncotarget.2944

Figure 3. Prognostic impact of high FGFR1 amplification and low/no amplification on DFS and OS.

Figure 3

(A) The median DFS of the high FGFR1 amplification group was significantly shorter compared with low/no FGFR1 amplification group (P=0.019) (B) The median OS of high FGFR1 amplification group demonstrated significantly shorter than low/no FGFR1 amplification group (P=0.022).